Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
54 hedge funds and large institutions have $2.8M invested in Navidea Biopharmaceuticals Inc. in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 54 → 54 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.6% less ownership
Funds ownership: 8.15% → 7.56% (-0.6%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
87% less capital inflows, than outflows
Capital inflows: $38.3K | Capital outflows: $303K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$12.6K |
| 2 |
Virtu Financial
New York
|
+$7.5K |
| 3 |
JP Morgan Chase
New York
|
+$5.49K |
| 4 |
Sound Income Strategies
Ft Lauderdale,
Florida
|
+$3.13K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
-$148K |
| 2 |
Sowell Financial Services
North Little Rock,
Arkansas
|
-$24.5K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$21.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$21.5K |
| 5 |
Guggenheim Capital
Chicago,
Illinois
|
-$18K |
NAVB Hedge Fund Activity: Q2 2018 in Review
54 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2018, worth a combined $2.8M — down 41% from $4.75M a quarter earlier.
Fund positioning in NAVB was balanced in Q2 2018: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 9 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $12.6K. The largest seller was Bridgeway Capital Management, cutting an estimated $148K.
- 54 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $2.8M of Navidea Biopharmaceuticals Inc. stock for Q2 2018, down 41% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2018 and 6 closed out, a net change of 0 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2018 was Invesco, an estimated $12.6K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2018 was Bridgeway Capital Management, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2018.